

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	15	-	11	=	4	\$ 9	\$36.00
INDEPENDENT	2	-	1	=	1	\$ 42	\$42.00
_____ FIRST PRESENTATION OF A MULTIPLE CLAIM						\$140	\$0.00
						TOTAL	\$78.00

Appl. No. 09/889,300


- ☐ Petition for ( ) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☐ No fee is required.
- ☒ Check(s) in the amount of \$78.00 is(are) enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By



Leonard R. Svensson, #30,330

LRS/SWG/sbp  
0147-0229P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000


Attachment

(Rev. 09/27/01)


I hereby certify that this correspondence is being  
reproduced by the United States Patent Service for the  
purpose of the Official Gazette of the United States  
Patent and Trademark Office. In an envelope to  
be sent to the Commissioner of Patents and Trademarks, Washington, D.C.

D.C. 20231 on: Aug. 8, 2002  
(Date of deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP



Aug. 8, 2002  
(Date of filing)



COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

AUG 20 2002

TECH CENTER 1600/2900 PATENT  
0147-0229P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: ECKERT, Helmut et al. Conf.: 2392  
Appl. No.: 09/889,300 Group: 1642  
Filed: September 13, 2001 Examiner: YAEN, Christopher  
For: USE OF ANTIBODIES FOR THE BACCVIINATION  
CANCER

AMENDMENT

Assistant Commissioner for Patents  
Washington, DC 20231

August 8, 2002

Sir:

In response to the Office Action issued May 8, 2002, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE CLAIMS:

(Please amend the claims as follows:)

1. (Twice Amended) A pharmaceutical composition for (vaccination) to actively immunize cancer patients for the (prevention) of the development of metastasis and treatment of cancer disease (comprising at least one antibody directed against the cellular membrane antigen EpCAM.

5. (Twice Amended) The pharmaceutical composition of any one of claims 1-3, wherein said antibody has the same

H  
9/13  
KJ  
3-21-03

36.00 OF  
42.00 OF  
B1

B2

08/15/2002 AHARI  
01 FC:203  
02 FC:202